Cosmos Health announced the launch of its new "18 Series" nutraceutical platform in the United States, debuting three products—Noor18™, Liv18™, and Cur18™—that each meet patented ingredient, peer‑reviewed clinical evidence, and precise dosing criteria derived from clinical trials. The products target healthy aging and beauty, liver and metabolic support, and inflammation and mobility, respectively, and together address a $7.8 billion U.S. market.
The launch marks a significant expansion of Cosmos Health’s vertically integrated model into the U.S. nutraceutical market. By adding these products to its platform, the company creates a cumulative value effect, positioning itself to capture a sizable share of a high‑growth segment while leveraging its existing manufacturing, distribution, and brand infrastructure. The company projects high gross margins—around 75% for Liv18™—reflecting a strategic shift toward higher‑margin, science‑backed offerings.
Financially, Cosmos Health reported Q1 2026 revenue of $18.82 million and an EPS of –$0.04, compared with Q1 2025 revenue of $13.71 million and a gross margin of 14.95%. The full‑year 2025 revenue was $65.27 million with a gross margin of 12.10%. These figures illustrate the company’s ongoing path to profitability while investing in new product development.
CEO Greg Siokas said, "We chose 18 because it earns its meaning twice. Once in the laboratory, where science changed what we know about absorption. And once in the deepest tradition of human wellness, where 18 has always meant life. When consumers see the '18', they should know: this product has been held to the highest standard we know how to set." He added, "With Cur18™, we are introducing a clinically studied, patented formulation designed to enhance bioavailability and deliver meaningful results. This launch reflects our broader strategy to expand in the U.S. market with differentiated, science‑based nutraceutical products." Siokas also noted, "The completion of Phase 1 execution for Liv18™ is a significant milestone – and one that is ahead of schedule – as we prepare for its commercial rollout in the United States."
The platform strategy aims to build a portfolio of up to 18 clinically validated products, providing a scalable model that can generate incremental revenue and margin expansion as more items are added. By focusing on patented ingredients and rigorous clinical evidence, Cosmos Health seeks to differentiate itself from competitors that rely more heavily on marketing claims, potentially enabling premium pricing and stronger consumer trust.
The launch of the "18 Series" represents a major operational milestone for Cosmos Health, signaling a strategic pivot toward higher‑margin, science‑driven nutraceuticals and positioning the company to capture a significant portion of the U.S. market while reinforcing its vertically integrated business model.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.